A Phase 3 Study of HS-20094 in Patients With T2DM

NCT07156539 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

546

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: HS-20094 Injection
DRUG: Dulaglutide Injection

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.